Patents Examined by Savitha M Rao
  • Modulators of GTPases and their use
    Patent number: 11672779
    Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type I), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp. infections, especially including Entamoeba histolytica.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: June 13, 2023
    Assignee: UNM Rainforest Innovations
    Inventors: Angela Wandinger-Ness, Laurie Hudson, Larry Sklar, Zurab Surviladze, Tudor Oprea
  • Pharmaceutical combination, composition and compound preparation containing glucokinase activator and K-ATP channel blocker, preparation method therefor and use thereof
    Patent number: 11666556
    Abstract: The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: June 6, 2023
    Assignee: HUA MEDICINE (SHANGHAI) LIMITED
    Inventors: Li Chen, Yongguo Li, Gaosen Wang, Huisheng Gao
  • Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof
    Patent number: 11666568
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a BCL-2 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 6, 2023
    Assignee: ACETYLON PHARMACEUTICALS, INC.
    Inventors: Nathan Moore, Chengyin Min
  • Tranexamic acid oral solution
    Patent number: 11666532
    Abstract: Methods and compositions are provided for treating a patient having a bleeding disorder during or after a dental procedure to reduce bleeding or need for factor replacement therapy. Aqueous pharmaceutical compositions are provided comprising tranexamic acid, sodium carboxymethyl cellulose, Tween® 20, and menthol wherein the composition exhibits good long term stability, little to no discoloration over time, and reduced bitterness compared to a control solution of tranexamic acid and water.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: June 6, 2023
    Assignee: Hyloris Developments SA
    Inventors: Mary Beth G. Erstad, Thomas Gerner Jacobsen, Mohammad Alkhalili, L. Diane Bruce, Paul Hafey
  • Application of combination of polyethylene glycol and local anesthetic in non-narcotic analgesia
    Patent number: 11654198
    Abstract: The invention discloses use of a conjugate of polyethylene glycol and a local anesthetic in non-anesthetic analgesia. A local anesthetic is prepared into a prodrug or a sustained release preparation, wherein a high molecular polymer such as polyethylene glycol in the prodrug is covalently bonded with a local anesthetic, and auxiliary materials with a sustained release effect in the sustained release preparation are non-covalently bonded to the local anesthetic. After administration, there is no anesthesia and analgesic effect before the release of the free local anesthetic. After the free local anesthetic is released, an analgesic effect is achieved.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 23, 2023
    Assignee: JENKEM TECHNOLOGY CO., LTD. (TIANJIN)
    Inventors: Zewang Feng, Jinliang Wang, Yanli Xiong, Juan Shi, Xuan Zhao
  • Darunavir combination formulations
    Patent number: 11654150
    Abstract: This invention relate to solid oral dosage forms of tire HIV inhibitor Darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulation thereof.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: May 23, 2023
    Assignee: Janssen Sciences Ireland UC
    Inventors: Urbain Alfons C. Delaet, Philip Erna H. Heyns, Eugeen Maria Jozef Jans, Roel Jos M. Mertens, Geert Van Der Avoort
  • Agent for elevating nitric oxide concentration
    Patent number: 11654125
    Abstract: An agent for elevating nitric oxide (NO) concentration comprising glutathione or a salt thereof as an active ingredient; an agent for elevating NO concentration comprising glutathione or a salt thereof as an active ingredient for preventing or ameliorating a vascular endothelial malfunction-related symptom, or dilating blood vessels or promoting blood flow by elevating NO concentration; and a method for elevating NO concentration by ingesting glutathione or a salt thereof.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: May 23, 2023
    Assignee: KYOWA HAKKO BIO CO., LTD.
    Inventors: Masahiko Morita, Ayako Kamimura
  • Storage-stable ready-to-use formulations of tigecycline
    Patent number: 11654151
    Abstract: Liquid parenteral formulations are provided that include tigecycline and at least one or more pharmaceutically acceptable excipient or adjuvant, where the formulation is ready to use without additional steps for reconstitution at the time of administration.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: May 23, 2023
    Assignee: RK PHARMA INC.
    Inventors: Ravishanker Kovi, Jayaraman Kannappan, Sanjaysinh Fatesinh Thakor, Rahul Dixit
  • Methods and compositions for treating ectoparasite infestations
    Patent number: 11654128
    Abstract: The present application includes compositions for treating ectoparasite infestations, including killing ectoparasites and/or their ova, the compositions comprising one or more fatty acid esters and one or more linear polymeric siloxanes. Also included are kits comprising the compositions and methods of treating ectoparasite infestations, including methods of killing ectoparasites and/or their ova, using the compositions.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: May 23, 2023
    Assignee: Nuvo Pharmaceuticals (Ireland) Designated Activity Company
    Inventors: Bernard Joseph Chiasson, Robert Patrick Pearce, Chantal Paré
  • Azophenols as ERG oncogene inhibitors
    Patent number: 11648239
    Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: May 16, 2023
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Albert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava
  • Use of histone acetyltransferase inhibitor amidoximes as anti-proliferative agents
    Patent number: 11648217
    Abstract: Described herein is the use of bisamidoximes compounds for the treatment of HAT malfunction related pathologies.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: May 16, 2023
    Assignee: Texas Woman's University
    Inventors: Michael Bergel, James E. Johnson, Debra Dolliver, Sudheer Dhanireddy, Amon Gekombe
  • Loxapine film oral dosage form
    Patent number: 11648212
    Abstract: A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 16, 2023
    Assignee: Intelgenx Corp.
    Inventors: Mobarik Bilal, Rodolphe Obeid, Nadine Paiement
  • Methods for the treatment of abnormal involuntary movement disorders
    Patent number: 11648244
    Abstract: Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: May 16, 2023
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: David Stamler, Michael Fangching Huang
  • Pharmaceutical compositions
    Patent number: 11642356
    Abstract: In one example presented herein, is a pharmaceutical composition. The pharmaceutical composition can include halobetasol propionate, from 0 wt % to 3 wt % ethoxylated castor oil, a first compound, and a second compound. The first compound and the second compound can be selected from; N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate. The first compound and the second compound are not the same.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: May 9, 2023
    Assignee: Crescita Therapeutics Inc.
    Inventors: Wade Hull, Ngoc Truc-Chi Vo, Dominic King-Smith
  • Method for enhancing expression of antioxidant in epidermis
    Patent number: 11642369
    Abstract: To enhance expression of an antioxidant-related substance in an epidermis by using a diacylglycerol PEG adduct, a method for enhancing expression of an antioxidant-related substance in an epidermis is provided which includes applying a diacylglycerol PEG adduct to the epidermis as an active ingredient. The antioxidant-related substance is an oxidative stress response gene, an antioxidant enzyme, or an antioxidant protein. The diacylglycerol PEG adduct is selected from the group consisting of PEG-12 glycerol dimyristate (GDM12), PEG-12 glycerol distearate (GDS12), PEG-23 glycerol distearate (GDS23), PEG-23 glycerol dipalmitate (GDP23), and PEG-12 glycerol dioleate (GDO12).
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: May 9, 2023
    Assignee: J-Network, Inc.
    Inventors: Tatsuro Miyoshi, Brian Charles Keller, Akira Kodama
  • Hair care composition comprising antidandruff agent and polyquaternium-6
    Patent number: 11642353
    Abstract: Disclosed is a hair care composition comprising polyquaternium-6 and metal pyrithiones as antidandruff agents, wherein the composition is substantially free of glucan gum, nonionic guar gum and hydroxyethylcellulose. The composition of the present invention provides improved deposition of antidandruff agents such as zinc pyrithione on scalp.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: May 9, 2023
    Assignee: The Procter & Gamble Company
    Inventor: Kristine Suzanne So Yu
  • Patentiflorin A analogs as antiviral agents
    Patent number: 11638713
    Abstract: The present disclosure relates to patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: May 2, 2023
    Assignee: Hong Kong Baptist University
    Inventors: Hongjie Zhang, Wanfei Li, Nga Yi Tsang
  • Methods of inhibiting PCSK9
    Patent number: 11633379
    Abstract: Provided herein are methods for inhibiting PCSK9, reducing PCSK9 levels, and for treating or preventing related conditions and disorders, in a subject, which includes administering to a subject an effective amount of a compound which includes derivatized cycloalkyl[b]indoles, e.g., cyclopenta-, cyclohexa- and cyclohepta[b]indoles.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: April 25, 2023
    Assignees: Trustees of Dartmouth College, Oregon Health & Science University
    Inventors: Jimmy Wu, Sergio Fazio, Hagai Tavori
  • Compositions and methods for treating epilepsy, seizures and other conditions
    Patent number: 11633374
    Abstract: Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: April 25, 2023
    Assignee: TULEX PHARMACEUTICALS INC.
    Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala, Romona Bhattacharya
  • Parenteral formulation comprising siponimod
    Patent number: 11628137
    Abstract: The present invention relates to a pharmaceutical formulation of siponimod which can be administered parenterally. In particular, the present invention relates to a parenteral solution comprising siponimod and a method for preparing said solution.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: April 18, 2023
    Assignee: NOVARTIS AG
    Inventors: Rajesh Kumar, Mandala Rayabandla Sunil Kumar, Henricus Lambertus Gerardus Maria Tiemessen